Sapna Patel(@DrSapnaPatel) 's Twitter Profile Photo

Out study is finally out - it didn't feel apropos to tweet this last week with other important matters top of mind. Phase 2 Study Finds Nivolumab-Ipilimumab Combo Shows Activity in Metastatic ascopubs.org/doi/full/10.12… ASCO

account_circle
Letizia Palanga(@LetiziaPalanga) 's Twitter Profile Photo

Delighted to present my poster: “Parp inhibition as a possible therapeutic strategy in the treatment of Uveal Melanoma”, at Society Melanoma Res in Edinburgh.
Thanks to my PI Naomi Walsh and to my funding bodies IrishResearchCouncil CCRT

Delighted to present my poster: “Parp inhibition as a possible therapeutic strategy in the treatment of Uveal Melanoma”, at @SocietyMelanoma in Edinburgh. 
Thanks to my PI @naomiwalsh01 and to my funding bodies @IrishResearch @CCRTIreland

#uvealmelanoma #SMR2022
account_circle
Alex Shoushtari, MD(@alexshoushtari) 's Twitter Profile Photo

Five years ago today, I started my first patient on a Phase 1 study for . Today, we learned that it improves survival over single agent checkpoint blockade.

Thanks Immunocore and colleagues! So excited to offer this to pts soon! immunocore.com/news/immunocor…

account_circle
Ogul E. Uner, MD(@DrOgulUner) 's Twitter Profile Photo

Honored that my medical school thesis on timing in was featured as a top ocular oncology paper of the year at ! Grateful for our team Hans Grossniklaus Gustav Stålhammar.

Thanks Mike Zein for sending me this. Hope to be at AAO in person in the future!

Honored that my medical school thesis on #BAP1 timing in #uvealmelanoma was featured as a top ocular oncology paper of the year at #AAO2021! Grateful for our team @HEGrossniklaus @GStalhammar.

Thanks @eyemikezein for sending me this. Hope to be at AAO in person in the future!
account_circle
Marco Cordani #SinCienciaNoHayFuturo 🇮🇹🇪🇸(@marcord1986) 's Twitter Profile Photo

Prof Ramón Alemany from IDIBELL talking about the potential of oncolitic viruses in targeting PD-1/PD-L1 in . Very bad prognosis for uveal melanoma patients that do not get PD-1/PD-L1 treatment. Oncobell Symposium Alvaro Somoza

Prof Ramón Alemany from @idibell_cat talking about the potential of oncolitic viruses in targeting PD-1/PD-L1 in #uvealmelanoma. Very bad prognosis for uveal melanoma patients that do not get PD-1/PD-L1 treatment. @oncobellsympo @alvarosomoza
account_circle
Federica Giugliano, MD(@fedgiugliano) 's Twitter Profile Photo

❕Tebentafusp improved OS in Metastatic compared to investigator’s choice in front line setting

❔New standard?

nejm.org/doi/full/10.10…

NEJM

❕Tebentafusp improved OS in Metastatic #UvealMelanoma compared to investigator’s choice in front line setting

❔New standard? 

nejm.org/doi/full/10.10…

@NEJM #oncology #melanoma
account_circle
KyleighMRF(@KyleighMrf) 's Twitter Profile Photo

Proud to recognize Melanoma Research Foundation research grant recipients (left to right) Richard Carvajal, MD, Andrew Aplin,PhD, Stefan Kurtenbach, PhD, Bill Harbour,MD and Hunter Shain over $2,000,000 in research funding to-date!

Proud to recognize @CureMelanoma research grant recipients (left to right) Richard Carvajal, MD, Andrew Aplin,PhD, Stefan Kurtenbach, PhD, Bill Harbour,MD and @ShainLab over $2,000,000 in #uvealmelanoma research funding to-date!
account_circle